Clinical trials: Prostate Cancer Stage
Recurrent Prostate Cancer, Stage I Prostate Cancer
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
This phase II trial studies how well lapatinib ditosylate works in treating patients with a rising prostate-specific antigen (PSA), a protein made by the prostate gland, indicating that prostate cancer has come back after…
- Conditions
- Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT00103194
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer
Evaluate the efficacy of Abraxane in first line chemotherapy of patients with hormone refractory metastatic prostate cancer, based on prostate specific antigen (PSA) response
- Trial name
- NCT00284752
- Testing
- Abraxane
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Kaiser Permanente
Patients With High-risk Prostate Cancer
Circulating Tumor Cells in High-Risk Prostate Cancer Treated With High-dose Radiotherapy and Hormone Therapy
The detection and quantification of Circulating tumor cells CTCs in peripheral blood of patients with prostate adenocarcinoma may be useful at least for: Getting a correct stratification of patients with high-risk prostate cancer…
- Trial name
- NCT01800058
- Where
- 3 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Adenocarcinoma of Prostate, Adenocarcinoma of the Prostate Stage I
Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial
This is a psychosocial/behavioral study and does not involve administration of any treatment or diagnostic procedures. We will use a randomized trial to test the hypothesis that a decision analysis model that provides…
- Conditions
- Adenocarcinoma of Prostate, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III
- Trial name
- NCT02024685
- Testing
- Personalized Treatment Recommendations, Standard patient-physician counseling interaction
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Case Comprehensive Cancer Center
Malignant Solid Tumors, Lymphoma
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.
- Conditions
- Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03205176
- Testing
- AZD5153, Olaparib
- Where
- 4 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Castration Resistant Prostate Cancer
N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer
Background: Prostate cancer does not trigger a strong immune response in the body. Hormone therapy, to reduce levels of testosterone in the body, can be helpful to treat some prostate cancers.
- Trial name
- NCT05445882
- Testing
- Bintrafusp alfa, N-803, BN-Brachyury
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer
This study will evaluate the use of magnetic resonance imaging (MRI) for guiding placement of hollow needles into the prostate gland for delivering internal radiation therapy to patients with prostate cancer.
- Trial name
- NCT00039624
- Testing
- Brachytherapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Preoperative Radiation Therapy for High Risk Prostate Cancer
This is a Phase I dose-escalation study of moderate dose radiation therapy prior to radical prostatectomy for patients with high-risk localized disease.
- Trial name
- NCT01041326
- Testing
- Radiation, Radical Prostatectomy
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Metastatic Prostate Cancer
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.
- Trial name
- PETRANHA (NCT05367440)
- Testing
- AZD5305, Enzalutamide, Abiraterone Acetate
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
This phase I trial tests the safety, side effects and best dose of radioligand therapy (lutetium Lu 177 PSMA-10.1 [177Lu-rhPSMA-10.1]) after prostate specific membrane antigen (PSMA) positron emission tomography (PET)-guided…
- Trial name
- NCT06105918
- Testing
- Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Emory University
Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8
Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance
This phase IV trial studies the effects of testosterone replacement therapy (TRT) on treatment outcomes in hypogonadal men with prostate cancer that has not spread to other parts of the body (localized) and who are on active…
- Conditions
- Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- NCT06733350
- Testing
- Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
Following a radical prostatectomy and lymph node sampling, eligible patients will undergo post-operative radiation therapy, concurrent weekly docetaxel chemotherapy , and hormonal therapy (Casodex daily and Zoladex every 3 months…
- Trial name
- NCT00669162
- Testing
- Docetaxel, Radiation Therapy, Casodex and Zoladex (or Lupron)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Kansas Medical Center
Prostate Cancer
A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer
Some men newly diagnosed with prostate cancer do not require immediate treatment. Rather, they can be followed closely with regular physical exams, blood work and repeated biopsies of the prostate.
- Trial name
- NCT01858688
- Testing
- Multiparametric MRI, Prostate biopsy
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma Prostate
A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.
Open label, single arm, phase II multicentre study designed to determine the clinical benefit, as measured by 3-months disease control rate (DCR) provided by enzalutamide in metastatic Castration Resistant Prostate Cancer…
- Trial name
- EXCALIBUR (NCT03103724)
- Testing
- Xtandi
- Where
- Italy
- Volunteers
- 68 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Prostate Cancer
Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer
RATIONALE: Dietary supplementation with soy may keep prostate cancer from growing in patients planning to undergo surgery. PURPOSE: This randomized phase II trial is studying a soy supplement to see how well it works compared to…
- Trial name
- NCT00345813
- Testing
- soy isoflavones, soy protein isolate
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer Surgery, Prostate Cancer Metastatic Disease
Safety and Efficacy of OTL78
This is a trial to assess the accuracy of an imaging agent, PSMA targeted fluorescent dye OTL78 (zopocianine), in combination with Near InfraRed (NIR) fluorescent imaging, to improve the detection of malignant (growing in an…
- Trial name
- NCT07725523
- Testing
- 0.06 mg/kg ZOPOCIANINE given 1-7 days prior to surgery
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Clinton Bahler
Castration-Resistant Prostate Cancer (CRPC)
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.
- Trial name
- NCT01534052
- Testing
- Enzalutamide
- Where
- 7 sites in United States, Moldova and 1 more
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer
One of the usual approaches to treating intermediate-risk prostate cancer is a type of radiation therapy called SBRT (stereotactic body radiation therapy).
- Trial name
- NCT04997018
- Testing
- Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 91 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Rationale: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known if vaccine therapy is effective for prostate cancer.
- Trial name
- NCT00005947
- Testing
- sipuleucel-T
- Where
- 34 sites in United States
- Volunteers
- 127 people
- Sponsor
- Dendreon
Prostate Carcinoma
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
This phase II trial studies how well 18F-DCFPyL positron emission tomography (PET)/magnetic resonance imaging (MRI) works for the diagnosis of prostate cancer in men with a PSA greater than or equal to 2 ng/mL.
- Trial name
- NCT04910425
- Testing
- Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol
- Where
- United States
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.